4,6-二氯-3-[(E)-(2-氧代-1-苯基-3-吡咯烷基亚基)甲基]-1H-吲哚-2-羧酸 | 166974-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4,6-二氯-3-[(E)-(2-氧代-1-苯基-3-吡咯烷基亚基)甲基]-1H-吲哚-2-羧酸
• 中文别名: T-丁基反-17-溴-471013-四氧杂；4,6-二氯-3-((2-氧亚基-1-苯基吡咯烷-3-亚基)甲基)-1H-吲哚-2-羧酸
• 英文名称: 4,6-dichloro-3-[(E)-(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid
• 英文别名: 5,7-dichloro-1-(2-oxo-1-phenyl-pyrrolidin-3-ylidenemethyl)-1H-indene-2-carboxylic acid；(E)-4,6-dichloro-3-(2-oxo-1-phenyl-pyrrolidin-3-ylidenemethyl)-1H-indole-2-carboxylic acid；GW196771；GV196771A；1H-Indole-2-carboxylic acid, 4,6-dichloro-3-((2-oxo-1-phenyl-3-pyrrolidinylidene)methyl)-, (E)-；4,6-dichloro-3-[(E)-(2-oxo-1-phenylpyrrolidin-3-ylidene)methyl]-1H-indole-2-carboxylic acid
• CAS: 166974-22-7
• 化学式: C₂₀H₁₄Cl₂N₂O₃
• 分子量: 401.249
• InChiKey: VDIRQCDDCGAGET-DHZHZOJOSA-N

物化性质

• 沸点：
  644.9±55.0 °C(Predicted)
• 密度：
  1.560±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  73.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,6-二氯-3-[(E)-(2-氧代-1-苯基-3-吡咯烷基亚基)甲基]-1H-吲哚-2-羧酸 在 四丁基溴化铵 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 5-O-[5,7-dichloro-1-(2-oxo-1-phenyl-pyrrolidin-3-ylidenemethyl)-1H-indene-2-carboxylate]-ribofuranosyl adenine
  参考文献：
  名称：

  Synthesis and biological evaluation of pro-drugs of GW196771, a potent glycine antagonist acting at the NMDA receptor

  摘要：

  GW196771 is a potent antagonist of the modulatory glycine site of the N-methyl-D-aspartate (NMDA) receptor exhibiting outstanding in vivo profile in different animal models of chronic pain. With the aim to maximize the drug delivery to the target organs a suitable "pro-drug approach" was attempted; in this regards two conjugates of GW196771 with nutrients actively transported into the brain, namely adenosine and glucose, were prepared and investigated. These compounds, were evaluated in vitro in terms of their stability in rat plasma and in vivo on rats. Although an improvement was observed in terms of brain penetration of the esters vs. the parent compound, the amount of the latter did not increase significantly, probably due to some degradation events in the brain, different from the expected ester hydrolysis, resulting in a reduced availability of GW196771.

  DOI：

  10.1016/j.farmac.2005.03.007
• 作为产物：
  描述：

  在 盐酸 、 lithium hydroxide 、 三甲基硅烷化重氮甲烷 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 12.17h， 生成 4,6-二氯-3-[(E)-(2-氧代-1-苯基-3-吡咯烷基亚基)甲基]-1H-吲哚-2-羧酸
  参考文献：
  名称：

  Unusual synthesis of new glycine antagonists via sequential aldol condensation-lactonization-elimination reaction

  摘要：

  Compounds 2 and 3 were designed in older to probe the North-East region of the strichnine-insensitive glycine binding site of the NMDA receptor. The two products were obtained readily by a tandem aldol condensation-lactonization-elimination step which affords the desired E isomer with complete regioselection. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00284-4

文献信息

• Indole derivatives
  申请人：Glaxo Wellcome SpA

  公开号：US05760059A1

  公开（公告）日：1998-06-02

  This invention relates to compounds of formula ##STR1## or a salt, or metabolically labile ester thereof wherein R represents a group selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, SO.sub.2 R.sub.2 or COR.sub.2 wherein R.sub.2 represents hydroxy, methoxy, amino, alkylamino, or dialkylamino; m is zero or an integer 1 or 2; R.sub.1 represents a cycloalkyl, bridged cycloalkyl, heteroaryl, bridged heterocyclic or optionally substituted phenyl or fused bicyclic carbocylic group; A represents a C.sub.1-4 alkylene chain or the chain (CH.sub.2).sub.p Y(CH.sub.2).sub.q wherein Y is O, S(O)n or NR.sub.3 and which chains may be substituted by one or two groups selected from C.sub.1-6 alkyl optionally substituted by hydroxy, amino, alkylamino or dialkylamino, or which chains may be substituted by the group .dbd.O; R.sub.3 represents hydrogen, alkyl or a nitrogen protecting group; n is zero or an integer from 1 to 2; p is zero or an integer from 1 to 3; q is zero or an integer from 1 to 3 with the proviso that the sum of p+q is 1, 2 or 3, which are antagonists of excitatory amino acids, to processes for the preparation and to other use in medicine.

  这项发明涉及以下式的化合物##STR1##或其盐，或代谢易降解的酯，其中R代表从卤素、烷基、烷氧基、氨基、烷基氨基、二烷基氨基、羟基、三氟甲基、三氟甲氧基、硝基、氰基、SO.sub.2 R.sub.2或COR.sub.2中选择的基团，其中R.sub.2代表羟基、甲氧基、氨基、烷基氨基或二烷基氨基；m为零或整数1或2；R.sub.1代表环烷基、桥环烷基、杂环烷基、桥接杂环烷基或可选择取代的苯基或融合的双环碳环基团；A代表C.sub.1-4烷基链或链(CH.sub.2).sub.p Y(CH.sub.2).sub.q，其中Y为O、S(O)n或NR.sub.3，这些链可以被一个或两个选自C.sub.1-6烷基（可选择地取代为羟基、氨基、烷基氨基或二烷基氨基）的基团取代，或这些链可以被基团.dbd.O取代；R.sub.3代表氢、烷基或氮保护基；n为零或整数1到2；p为零或整数1到3；q为零或整数1到3，但p+q的总和为1、2或3，这些化合物是兴奋性氨基酸的拮抗剂，用于制备的方法以及在医学中的其他用途。
• [EN] INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN<br/>[FR] COMPOSÉS D'INDOLE ET PROCÉDÉS DE TRAITEMENT DE LA DOULEUR VISCÉRALE
  申请人：NEURAXON INC

  公开号：WO2009062319A1

  公开（公告）日：2009-05-22

  The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.

  该发明涉及治疗哺乳动物体内因一氧化氮合酶（NOS）或5-羟色胺受体5HT1D/1B的作用引起的内脏疼痛或疾病的方法，通过向需要治疗的患者施用式(I)的吲哚化合物的治疗有效量，或其药学上可接受的盐或前药。该发明的方法还可以包括额外治疗剂的施用。该发明还涉及式(I)的新化合物、其药物组合物以及解决对映体混合物的方法。
• 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY
  申请人：Annedi Subhash C.

  公开号：US20090131503A1

  公开（公告）日：2009-05-21

  The present invention relates to novel 3,5-substituted indole compounds of Formula (I) having nitric oxide synthase (NOS) inhibitory activity together with inhibitory activity at the norepinephrine transporter (NET), to pharmaceutical and diagnostic compositions containing them, and to their medical use.

  本发明涉及具有一氧化氮合酶（NOS）抑制活性以及对去甲肾上腺素转运蛋白（NET）具有抑制活性的新型3,5-取代吲哚化合物（I）的公式，以及含有它们的药用和诊断组合物，以及它们的医疗用途。
• Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity
  申请人：Renton Paul

  公开号：US20080214613A1

  公开（公告）日：2008-09-04

  The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.

  本发明涉及具有双重一氧化氮合酶（NOS）抑制活性和μ-阿片受体激动活性的苯并咪唑化合物，以及包含它们的药物和诊断组合物，以及它们的医学用途，特别是作为治疗或预防慢性疼痛、急性疼痛、偏头痛和神经病性疼痛的化合物。
• Substituted indole compounds having NOS inhibitory activity
  申请人：Maddaford Shawn

  公开号：US20060258721A1

  公开（公告）日：2006-11-16

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

  本发明涉及一种一氧化氮合酶（NOS）的抑制剂，特别是那些选择性地抑制神经型一氧化氮合酶（nNOS）而不是其他NOS同工酶的抑制剂。本发明的NOS抑制剂，单独或与其他药用活性剂结合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥术（CABG）、伴或不伴有先兆的偏头痛、伴有疼痛性过敏的偏头痛、中枢性中风后疼痛（CPSP）、神经痛、吗啡/阿片类药物引起的耐受性和过度疼痛等疾病。